Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
07/21/2022 | Press release | Distributed by Public on 07/21/2022 13:12
Please select the service you want to use:
Smartlinks | Olympique Lyonnais Groupe SA | Company News | Public Companies | Sports Teams and Clubs | London Stock Exchange (LSE) | Börse Frankfurt | Börse Berlin | Börse München | Börse Stuttgart | OTC Markets | Turquoise | Euronext Paris | Cboe BXE Europe | Cboe CXE Europe | Cboe Off Exchange | Börse Berlin Equiduct Trading | SIGMA X MTF | Euronext Block MTF
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact